Skip to content
Study details
Enrolling now

Radiation Therapy Trial

ECOG-ACRIN Cancer Research Group
NCT IDNCT02734537ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

189

Study length

about 11 years

Ages

18+

Locations

640 sites in AK, AL, AR +44

What this study is about

This trial is testing whether radiation therapy, alone or with cisplatin, is effective for people who have had surgery for squamous cell carcinoma of the head and neck. Radiation uses high-energy x-rays to kill cancer cells. Cisplatin is a chemotherapy drug that works in different ways to stop tumor growth.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Laboratory Biomarker Analysis
  • 2.Receive Intensity-Modulated Radiation Therapy
  • 3.Take Cisplatin

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Injection / IVInjection / IV

How treatment is administered

Treatment Assignment
Randomized (Open Label)

You are randomly assigned, but you will know your treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

cisplatin (Platinum chemotherapy; crosslinks DNA to stop replication)

Drug routes

injection, intravenous

Endpoints

Primary: Disease-free survival in patients with stage III-IV disease and disruptive p53 mutation

Secondary: Disease-free survival in patients with stage III-IV disease and non-disruptive p53 mutation, Disease-free survival in patients with stage III-IV disease and wild type p53 mutation, Incidence of adverse events graded using Common Terminology Criteria for Adverse Events version 4, p53 as a predictive marker of recurrence

Procedures

radiation

Body systems

Oncology